85 related articles for article (PubMed ID: 22958645)
1. Active liposomal loading of a poorly soluble ionizable drug.
Park K
J Control Release; 2012 Sep; 162(2):475. PubMed ID: 22958645
[No Abstract] [Full Text] [Related]
2. Enhanced active liposomal loading of a poorly soluble ionizable drug using supersaturated drug solutions.
Modi S; Xiang TX; Anderson BD
J Control Release; 2012 Sep; 162(2):330-9. PubMed ID: 22800581
[TBL] [Abstract][Full Text] [Related]
3. Liposome transport of hydrophobic drugs: gel phase lipid bilayer permeability and partitioning of the lactone form of a hydrophobic camptothecin, DB-67.
Joguparthi V; Xiang TX; Anderson BD
J Pharm Sci; 2008 Jan; 97(1):400-20. PubMed ID: 17879989
[TBL] [Abstract][Full Text] [Related]
4. Determination of intraliposomal pH and its effect on membrane partitioning and passive loading of a hydrophobic camptothecin, DB-67.
Joguparthi V; Feng S; Anderson BD
Int J Pharm; 2008 Mar; 352(1-2):17-28. PubMed ID: 18065174
[TBL] [Abstract][Full Text] [Related]
5. Molecular dynamics simulations and experimental studies of binding and mobility of 7-tert-butyldimethylsilyl-10-hydroxycamptothecin and its 20(S)-4-aminobutyrate ester in DMPC membranes.
Xiang TX; Jiang ZQ; Song L; Anderson BD
Mol Pharm; 2006; 3(5):589-600. PubMed ID: 17009858
[TBL] [Abstract][Full Text] [Related]
6. Semisynthesis of DB-67 and other silatecans from camptothecin by thiol-promoted addition of silyl radicals.
Du W; Kaskar B; Blumbergs P; Subramanian PK; Curran DP
Bioorg Med Chem; 2003 Feb; 11(3):451-8. PubMed ID: 12517440
[TBL] [Abstract][Full Text] [Related]
7. Expect the unexpected-screen your screens.
Ravivarapu H; Redkar S
J Pharm Sci; 2011 May; 100(5):1996. PubMed ID: 21374629
[No Abstract] [Full Text] [Related]
8. [A symphony for the camptothecins].
Lansiaux A; Bailly C
Bull Cancer; 2003 Mar; 90(3):239-45. PubMed ID: 12801826
[TBL] [Abstract][Full Text] [Related]
9. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine.
Koo OM; Rubinstein I; Onyuksel H
Nanomedicine; 2005 Mar; 1(1):77-84. PubMed ID: 17292061
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous drug release at different rates from biodegradable polyurethane foams.
Sivak WN; Zhang J; Petoud S; Beckman EJ
Acta Biomater; 2009 Sep; 5(7):2398-408. PubMed ID: 19398389
[TBL] [Abstract][Full Text] [Related]
11. Dimeric camptothecin derived phospholipid assembled liposomes with high drug loading for cancer therapy.
Fang S; Hou Y; Ling L; Wang D; Ismail M; Du Y; Zhang Y; Yao C; Li X
Colloids Surf B Biointerfaces; 2018 Jun; 166():235-244. PubMed ID: 29604567
[TBL] [Abstract][Full Text] [Related]
12. The comparison of biophysical properties of DB-67 and its ester DB-67-4ABTFA determined by fluorescence spectroscopy methods.
Kruszewski S; Ziomkowska B; Cyrankiewicz M; Wybranowski T
Biosystems; 2008 Dec; 94(3):270-5. PubMed ID: 18718502
[TBL] [Abstract][Full Text] [Related]
13. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo.
Tardi PG; Gallagher RC; Johnstone S; Harasym N; Webb M; Bally MB; Mayer LD
Biochim Biophys Acta; 2007 Mar; 1768(3):678-87. PubMed ID: 17208196
[TBL] [Abstract][Full Text] [Related]
14. Factors affecting microencapsulation of drugs in liposomes.
Kulkarni SB; Betageri GV; Singh M
J Microencapsul; 1995; 12(3):229-46. PubMed ID: 7650588
[TBL] [Abstract][Full Text] [Related]
15. Copper-topotecan complexation mediates drug accumulation into liposomes.
Taggar AS; Alnajim J; Anantha M; Thomas A; Webb M; Ramsay E; Bally MB
J Control Release; 2006 Aug; 114(1):78-88. PubMed ID: 16842880
[TBL] [Abstract][Full Text] [Related]
16. Encapsulation of flavonoids in liposomal delivery systems: the case of quercetin, kaempferol and luteolin.
Huang M; Su E; Zheng F; Tan C
Food Funct; 2017 Sep; 8(9):3198-3208. PubMed ID: 28805832
[TBL] [Abstract][Full Text] [Related]
17. In brief: liposomal irinotecan (Onivyde) for pancreatic cancer.
Med Lett Drugs Ther; 2016 Jun; 58(1496):e76. PubMed ID: 27249099
[No Abstract] [Full Text] [Related]
18. Liposomal formulations of poorly soluble camptothecin: drug retention and biodistribution.
Flaten GE; Chang TT; Phillips WT; Brandl M; Bao A; Goins B
J Liposome Res; 2013 Mar; 23(1):70-81. PubMed ID: 23210622
[TBL] [Abstract][Full Text] [Related]
19. The effect of DB-67, a lipophilic camptothecin derivative, on topoisomerase I levels in non-small-cell lung cancer cells.
Bence AK; Mattingly CA; Burke TG; Adams VR
Cancer Chemother Pharmacol; 2004 Oct; 54(4):354-60. PubMed ID: 15197485
[TBL] [Abstract][Full Text] [Related]
20. The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma.
Lopez-Barcons LA; Zhang J; Siriwitayawan G; Burke TG; Perez-Soler R
Neoplasia; 2004; 6(5):457-67. PubMed ID: 15548354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
